Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has secured provisional approval and priority designation in The Bahamas for OCU400, creating a pathway to provide its investigational gene therapy to retinitis …
Ocugen Wins Bahamas Priority Path for OCU400 Gene Therapy Read More
CHESTERBROOK, PA — Persevere Therapeutics has dosed the first patient in a Phase 2a trial of misetionamide at the University of Pennsylvania’s Abramson Cancer Center, moving the experimental MYC inhibitor …
Persevere Begins Phase 2a Ovarian Cancer Trial at Penn Read More
YARDLEY, PA — Jubilant Therapeutics reported early clinical activity for JBI-802 in a Phase 1/2 trial of patients with myeloproliferative neoplasms, with dose-responsive platelet reductions observed across several disease subtypes …
Jubilant Reports Early Platelet Reductions With JBI-802 Read More
PLYMOUTH MEETING, PA — Adverse-event reports for Braeburn’s Brixadi remained low and relatively stable during its first 18 months on the U.S. market, according to a company-funded study examining federal …
Braeburn Study Finds Low Adverse-Event Reporting for Brixadi Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network is funding four quality-improvement projects aimed at reducing gaps in metastatic prostate cancer care, targeting disparities in access, inconsistent testing and …
NCCN Funds Projects to Close Gaps in Prostate Cancer Care Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration finalized an expedited regulatory pilot that will pair drug companies with qualified research institutions to shorten the path to first-in-human clinical …
FDA Opens Expedited Drug Trial Pilot to Cut Development Delays Read More
WILMINGTON, DE — AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab significantly extended overall survival in a Phase III trial of first-line extensive-stage small cell lung cancer, potentially expanding treatment options for …
AstraZeneca Lung Cancer Combo Extends Survival in Phase III Read More WILMINGTON, DE — AstraZeneca’s experimental COPD drug tozorakimab reduced moderate and severe exacerbations by as much as 34% in two Phase III trials across a broad patient population, supporting a …
AstraZeneca COPD Drug Cuts Exacerbations in Phase III Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) selected the 200-mcg dose of its SkinJect patch for further development after completing a Phase 2 basal cell carcinoma study, supporting the …
ISYMI: Medicus Picks 200-Mcg SkinJect Dose for Gorlin Program Read More
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) received U.S. Food and Drug Administration clearance to begin a Phase 1 trial of PRT13722, moving its experimental KAT6A-targeting breast cancer drug …
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial Read More